Aclarion, Inc. Files 8-K on Security Holder Rights and Bylaws

TL;DR

Aclarion filed an 8-K on Jan 30th about changes to shareholder rights and bylaws.

AI Summary

Aclarion, Inc. filed an 8-K on January 30, 2025, reporting events that occurred on January 29, 2025. The filing indicates material modifications to the rights of security holders, amendments to its articles of incorporation or bylaws, and other events. It also includes financial statements and exhibits.

Why It Matters

This 8-K filing signals potential changes affecting Aclarion, Inc.'s shareholders and corporate governance, requiring investor attention.

Risk Assessment

Risk Level: medium — Filings related to modifications of security holder rights and amendments to corporate governance documents can indicate significant changes that may impact stock value.

Key Numbers

• 001-41358 — SEC File Number (Identifies the specific filing for Aclarion, Inc.)
• 47-3324725 — IRS Number (Tax identification number for Aclarion, Inc.)

Key Players & Entities

• Aclarion, Inc. (company) — Registrant
• January 30, 2025 (date) — Filing Date
• January 29, 2025 (date) — Earliest Event Date
• Delaware (jurisdiction) — State of Incorporation
• Nocimed, Inc. (company) — Former Company Name

FAQ

Key Financial Figures

• $14.55 million — blic offering to date are approximately $14.55 million before deducting underwriting discounts
• $10.5 million — e stockholders' equity of approximately $10.5 million as of January 30, 2025. Accordingly, t
• $2.5 million — es the Company to maintain a minimum of $2.5 million in stockholders' equity for continued l

Filing Documents

• acon_8k.htm (8-K) — 39KB
• acon_ex0301.htm (EX-3.1) — 9KB
• image_001.jpg (GRAPHIC) — 69KB
• 0001683168-25-000612.txt ( ) — 364KB
• acon-20250129.xsd (EX-101.SCH) — 4KB
• acon-20250129_def.xml (EX-101.DEF) — 26KB
• acon-20250129_lab.xml (EX-101.LAB) — 36KB
• acon-20250129_pre.xml (EX-101.PRE) — 25KB
• acon_8k_htm.xml (XML) — 6KB

03

Item 3.03 Material Modifications to Rights of Security Holders . To the extent required by Item 3.03 of Form 8-K, the information contained in Item 5.03 of this Current Report on Form 8-K is incorporated herein by reference.

03

Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. On January 29, 2025, Aclarion, Inc. (the "Company") filed a Certificate of Amendment to the Amended and Restated Certificate of Incorporation of the Company (the "Certificate of Amendment") with the Secretary of State of the State of Delaware to effect a reverse stock split of the Company's common stock at a ratio of one-for-three hundred thirty five (335). The Certificate of Amendment provides that the reverse stock split became effective as of 5:00 P.M. Eastern Time on January 29, 2025 (the "Effective Time"), at which time every three hundred thirty five (335) shares of the Company's issued and outstanding common stock were automatically combined into one (1) issued and outstanding share of common stock, without any change in the par value per share. The Certificate of Amendment provides that in the event a stockholder would otherwise be entitled to receive a fraction of a share of common stock, such stockholder shall receive one whole share of common stock in lieu of such fractional share and no fractional shares shall be issued. Trading of the Company's common stock on Nasdaq on a split-adjusted basis commenced at market open on January 30, 2025. The new CUSIP number for the common stock following the reverse stock split is 655187300. As a result of the reverse stock split, the Company's issued and outstanding shares of common stock were decreased from approximately 169.4 million pre-split shares to approximately 500,000 post-split shares. The reverse stock split did not change the number of authorized shares of the Company's common stock, which remains at 200 million shares. The reverse stock split will apply to the Company's outstanding warrants, stock options and restricted stock units. The number of shares of common stock into which these outstanding securities are convertible or exercisable will be adjusted as a result of the reverse stock split. The exercise prices o

01

Item 8.01 Other Events . As previously disclosed, on January 16, 2025 the Company closed an underwitten public offering of units, with each unit consisting of (i) one share of common stock or one pre-funded warrant, (ii) one Series A common warrant, and (iii) one Series B common warrant. The gross proceeds of the public offering to date are approximately $14.55 million before deducting underwriting discounts and commissions and estimated offering expenses payable by Aclarion. As a result of the public offering, the Company expects to have stockholders' equity of approximately $10.5 million as of January 30, 2025. Accordingly, the Company believes it has regained compliance with Nasdaq Listing Rule 5550(b)(1) (the "Stockholders' Equity Rule"), which requires the Company to maintain a minimum of $2.5 million in stockholders' equity for continued listing on The Nasdaq Capital Market.

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 3.1 Certificate of Amendment to the Amended and Restated Certificate of Incorporation of the Company dated January 29, 2025 104 Cover Page Interactive Data File - the cover page iXBRL tags are embedded within the Inline XBRL document 3

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ACLARION, INC. January 30, 2025 By: /s/ John Lorbiecki Name: John Lorbiecki Title: Chief Financial Officer 4

View Full Filing

View this 8-K filing on SEC EDGAR